Middle market companies engaging in research and development activities face new challenges due to new Section 174 rules. The required capitalization and amortization of R&D costs is problematic and confusing for many businesses, especially those in the technology and life sciences sectors.
Find answers here to some of the most frequently asked questions about the new rules and their ramifications, such as identification and treatment of R&D expenses, software development, state and local tax, international tax, legislative processes, administrative guidance, and advocacy.
KraftCPAs can help.
Call us at 615-242-7351 or complete the form below to connect with an advisor.